Genomic alterations that lead to oncogene activation and tumour suppressor loss are
important driving forces for cancer development. Although these changes can accumulate …

Many conventional chemotherapies used in cancer treatment exert their effect by inflicting
DNA damage. Highly proliferative tissues, as well as tumour cells, are particularly vulnerable …

Simple Summary PARP inhibitors (PARPi) are current treatment options for patients with
ovarian, breast, pancreatic or prostate cancer. Although PARPi have transformed the patient …

Guanine-rich DNA sequences that can adopt non–Watson-Crick structures in vitro are prevalent
in the human genome. Whether such structures normally exist in mammalian cells has, …

Emerging data demonstrate homologous recombination (HR) defects in castration-resistant
prostate cancers, rendering these tumours sensitive to PARP inhibition. Here we …

Background Germline mutations in the BRCA1 or BRCA2 (BRCA) genes predispose to
hereditary breast and ovarian cancer and, mostly in the case of BRCA2, are also prevalent in …

Mutations in the ATM tumor suppressor gene confer hypersensitivity to DNA-damaging
chemotherapeutic agents. To explore genetic resistance mechanisms, we performed genome-…

DNA double-strand breaks (DSBs) are perhaps the most toxic of all DNA lesions, with defects
in the DNA-damage response to DSBs being associated with various human diseases. …

Background The cell-cycle checkpoint kinase Chk1 is essential in mammalian cells due to
its roles in controlling processes such as DNA replication, mitosis and DNA-damage …

The DNA-damage checkpoint kinase Chk1 is essential in higher eukaryotes due to its role
in maintaining genome stability in proliferating cells. CHK1 gene deletion is embryonically …